Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...

For many life sciences start-ups, bringing on a GC early can be a strategic advantage. An experienced GC can help shape the company’s legal and operational foundation from day one, reducing reliance ...

While positive, for rare disease it represents the first step of a much longer journey – one that will determine whether ...

Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 antagonist class to reach the market. Licensed from fellow Japanese drugmaker ...

The Beijing biotech has been set up to tap into the growing interest in macrocyclic peptides as an emerging treatment ...

PHARMAP 2026 provides the platform for a key industry conversation: how leading pharmaceutical companies are further ...

AP01 has completed a phase 1b trial (ATLAS) in idiopathic pulmonary fibrosis (IPF) and has started an open-label extension in ...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Researchers in the US have said that advances in therapeutics are outpacing the development of diagnostics to guide their use, due to policy gaps and payment barriers around the world. The team, from ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

The conflict in the Middle East is sending shockwaves through the global economy and disrupting global trade.

Boehringer Ingelheim has amended its partnership with Click Therapeutics on a digital therapeutic (DTx) for schizophrenia, ...